Status:
COMPLETED
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
University of Bern
University of Zurich
Conditions:
Low Back Pain
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of...
Detailed Description
Background Drug therapy is an essential part of pain treatment. However, only a minor part of pain patients benefits from the available treatments or is able to tolerate the drugs. One important limi...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Low back pain with NRS\>2
- Chronic low back pain since more than 6 months
- Exclusion Criteria
- pregnancy
- use of pain medication other than paracetamol and ibuprofen in the last 7 days
- suspicion of radicular pain
- suspicion of intervertebral disk herniation
- foraminal intervertebral stenosis
- suspicion of polyneuropathy
- diabetes
- parkinson disease
- alzheimer disease
- glaucoma
- prostata hyperplasia or voiding problems
- known heart rhythm problems
- heart insufficiency NYHA 3-4
- Systemic inflammatory disease
- Ongoing oncologic disease
- drug or alcohol abuse
- Significant depressive disease (BDI-FS\>9)
Exclusion
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01179828
Start Date
July 1 2010
End Date
December 1 2015
Last Update
April 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andreas Siegenthaler
Dep. of Anesthesiolgy and Pain Therapy, Bern University Hospital, Switzerland, 3010 Bern